Holen Sie sich die Stockscreener-App
3.1199
2.81%
-0.0801
Schlusskurs vom Vortag:
$3.20
Offen:
$3.21
24-Stunden-Volumen:
32,283
Relative Volume:
0.01
Marktkapitalisierung:
$38.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.07%
1M Leistung:
+50.97%
6M Leistung:
+100.65%
1J Leistung:
-13.13%
1-Tages-Spanne:
$3.0568
$3.21
1-Wochen-Bereich:
$2.92
$3.225
52-Wochen-Spanne:
$1.345
$6.3699
Q 32 Bio Inc Stock (QTTB) Company Profile
Firmenname
Q 32 Bio Inc
Sektor
Branche
Telefon
781-999-0232
Adresse
830 WINTER STREET, WALTHAM
Vergleichen Sie QTTB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.1199 | 39.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.10 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.69 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.99 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.66 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.66 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | Raymond James | Strong Buy |
| 2024-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-17 | Eingeleitet | Guggenheim | Buy |
| 2024-05-21 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Bestätigt | BTIG Research | Neutral |
| 2022-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-12-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-11-01 | Eingeleitet | Oppenheimer | Perform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Q 32 Bio Inc Aktie (QTTB) Neueste Nachrichten
Fundamentals Check: Will Q32 Bio Inc stock gain from lower inflationWatch List & Consistent Profit Trading Strategies - moha.gov.vn
Q32 Bio Retains Mark Iwicki as Board Chair - TipRanks
Q32 Bio director Mark Iwicki withdraws resignation and will remain board chair - Investing.com
Why retail investors pile into Q32 Bio Inc. stockJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
How Q32 Bio Inc. stock trades before earningsWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
Why Q32 Bio Inc. stock remains on watchlistsJuly 2025 EndofMonth & Reliable Price Breakout Signals - DonanımHaber
Will Q32 Bio Inc. stock gain from lower inflationNew Guidance & Safe Entry Momentum Stock Tips - DonanımHaber
Can Q32 Bio Inc. stock deliver strong Q4 earningsMarket Trend Review & Breakout Confirmation Alerts - DonanımHaber
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Will Q32 Bio Inc stock gain from lower inflationWeekly Gains Summary & Fast Moving Market Watchlists - moha.gov.vn
Aug Technicals: Can Q32 Bio Inc stock attract ESG capital inflowsQuarterly Profit Review & Verified Momentum Stock Ideas - moha.gov.vn
Q32 Bio Insiders Benefit From Selling Stock At US$2.86 - simplywall.st
Stock Market Recap: Why millennials buy Spire Inc LGR stockInsider Buying & Safe Swing Trade Setups - BỘ NỘI VỤ
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Q32 Bio Inc. stock a defensive play in 2025Quarterly Profit Report & Accurate Technical Buy Alerts - Newser
Lee Kalowski, Q32 Bio CFO, sells $31k in shares By Investing.com - Investing.com UK
Is Q32 Bio Inc. stock recession proofWeekly Profit Report & Technical Analysis for Trade Confirmation - Newser
Q32 Bio CEO Morrison sells $77870 in stock By Investing.com - Investing.com South Africa
Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB) - GuruFocus
Lee Kalowski, Q32 Bio CFO, sells $31k in shares - Investing.com
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M - MSN
Nothing is Better Than Q32 Bio Inc (QTTB) stock at the moment - Setenews
Block Trades: Will CGEN stock remain a Wall Street favorite2025 Technical Overview & Consistent Profit Alerts - BỘ NỘI VỤ
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Q32 Bio (QTTB) Stock Analysis Report | Financials & Insights - Benzinga
Will Q32 Bio Inc. stock attract ESG investorsTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio Inc. (QTTB) Stock: Jumps on Akebia Acquisition of ADX-097 and Extended Runway - parameter.io
Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter
QTTB Stock Surges: Market Insight - StocksToTrade
Dow Dips 200 Points; Q32 Bio Shares Jump - inkl
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - inkl
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Q32 Bio sells complement inhibitor Adx-097 - marketscreener.com
Finanzdaten der Q 32 Bio Inc-Aktie (QTTB)
Es liegen keine Finanzdaten für Q 32 Bio Inc (QTTB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.16%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):